Close
4

Seqens Seqens

X

Company profile for ImmunoMet

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor that targets the OXPHOS pathway in mitochondria and decreases the energy supply of resistant cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with good tolerability and ImmunoMet anticipates initiating Phase 2 PoC ...
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor that targets the OXPHOS pathway in mitochondria and decreases the energy supply of resistant cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with good tolerability and ImmunoMet anticipates initiating Phase 2 PoC studies in oncology next year.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
ImmunoMet
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
JLABS@TMC 2450 Holcombe Blvd, Houston, TX 77021
Telephone
Telephone
(+1) 346-772-0318
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY